Your browser is no longer supported. Please, upgrade your browser.
OCUL Ocular Therapeutix, Inc. daily Stock Chart
Ocular Therapeutix, Inc.
Index- P/E- EPS (ttm)-1.98 Insider Own9.89% Shs Outstand57.37M Perf Week-11.78%
Market Cap672.13M Forward P/E- EPS next Y-0.66 Insider Trans5.36% Shs Float55.11M Perf Month18.95%
Income-102.90M PEG- EPS next Q-0.24 Inst Own54.80% Short Float12.58% Perf Quarter14.55%
Sales7.30M P/S92.07 EPS this Y-21.20% Inst Trans0.03% Short Ratio6.57 Perf Half Y61.28%
Book/sh0.09 P/B103.22 EPS next Y52.20% ROA-118.40% Target Price12.67 Perf Year184.97%
Cash/sh1.17 P/C7.97 EPS next 5Y- ROE- 52W Range2.46 - 12.42 Perf YTD135.19%
Dividend- P/FCF- EPS past 5Y6.60% ROI-187.80% 52W High-25.20% Beta1.84
Dividend %- Quick Ratio6.50 Sales past 5Y40.50% Gross Margin64.20% 52W Low277.64% ATR0.70
Employees161 Current Ratio6.50 Sales Q/Q128.60% Oper. Margin- RSI (14)44.92 Volatility6.11% 8.00%
OptionableYes Debt/Eq9.70 EPS Q/Q-11.90% Profit Margin- Rel Volume0.85 Prev Close9.69
ShortableYes LT Debt/Eq8.92 EarningsNov 05 AMC Payout- Avg Volume1.05M Price9.29
Recom1.80 SMA20-6.92% SMA502.51% SMA20031.61% Volume899,676 Change-4.13%
Aug-10-20Reiterated H.C. Wainwright Buy $10 → $13
Mar-03-20Upgrade Raymond James Outperform → Strong Buy
May-21-19Reiterated H.C. Wainwright Buy $12 → $9
May-21-19Downgrade Raymond James Strong Buy → Outperform $11 → $5
May-21-19Downgrade Cowen Outperform → Market Perform $13 → $3
Dec-03-18Reiterated Cantor Fitzgerald Overweight $22 → $24
Nov-15-18Initiated Raymond James Strong Buy $10
Sep-07-18Initiated Piper Jaffray Overweight
Oct-24-17Initiated Guggenheim Buy $12
Jul-26-17Initiated H.C. Wainwright Buy $10
Jul-12-17Reiterated Cantor Fitzgerald Overweight $35 → $21
Jun-23-17Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-10-17Initiated Cantor Fitzgerald Overweight $35
Nov-15-16Reiterated RBC Capital Mkts Outperform $30 → $32
Aug-11-16Initiated JMP Securities Mkt Outperform
Feb-17-16Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-13-15Initiated Morgan Stanley Overweight $24
Aug-05-15Initiated Nomura Buy $46
Apr-08-15Reiterated RBC Capital Mkts Outperform $50 → $48
Oct-23-20 07:00AM  
Oct-22-20 07:32AM  
Oct-14-20 06:30AM  
Oct-13-20 05:01PM  
Oct-08-20 08:00AM  
Oct-07-20 08:00AM  
Oct-06-20 08:00AM  
Sep-29-20 08:00AM  
Sep-21-20 01:41PM  
Sep-10-20 07:00AM  
Sep-08-20 07:00AM  
Sep-04-20 12:52PM  
Sep-03-20 07:00AM  
Aug-07-20 08:45AM  
Aug-06-20 04:08PM  
Aug-05-20 03:30PM  
Jul-31-20 07:00AM  
Jul-29-20 12:33PM  
Jul-23-20 07:00AM  
Jul-17-20 07:30AM  
Jul-15-20 07:00AM  
Jun-15-20 06:38PM  
Jun-14-20 08:24PM  
Jun-12-20 06:13AM  
Jun-10-20 08:00AM  
May-29-20 08:00AM  
May-27-20 09:40AM  
May-25-20 10:00AM  
May-22-20 04:19PM  
May-20-20 07:30AM  
May-19-20 04:44PM  
May-12-20 07:00AM  
May-11-20 07:00AM  
May-09-20 11:30PM  
May-08-20 08:43AM  
May-01-20 12:30PM  
Apr-28-20 07:00AM  
Apr-13-20 08:00AM  
Mar-31-20 04:56PM  
Mar-12-20 07:45PM  
Mar-05-20 08:00AM  
Mar-03-20 07:30AM  
Feb-27-20 12:30PM  
Feb-25-20 08:00AM  
Feb-23-20 07:10AM  
Feb-18-20 08:10AM  
Feb-07-20 08:00AM  
Jan-13-20 01:34PM  
Dec-23-19 03:58PM  
Dec-06-19 02:20PM  
Dec-04-19 05:56PM  
Nov-26-19 08:00AM  
Nov-14-19 08:00AM  
Nov-12-19 08:15AM  
Nov-08-19 04:01PM  
Nov-05-19 08:00AM  
Oct-30-19 10:33AM  
Oct-15-19 11:38AM  
Oct-01-19 04:24PM  
Sep-26-19 08:00AM  
Sep-24-19 08:00AM  
Aug-29-19 08:00AM  
Aug-23-19 11:24AM  
Aug-15-19 10:15PM  
Aug-14-19 11:56AM  
Aug-07-19 06:15PM  
Jul-30-19 10:38AM  
Jul-26-19 08:00AM  
Jul-18-19 06:26PM  
Jul-11-19 04:05PM  
Jul-09-19 08:00AM  
Jul-08-19 08:42AM  
Jul-01-19 08:00AM  
Jun-24-19 08:50AM  
Jun-23-19 03:53PM  
Jun-21-19 11:19AM  
Jun-10-19 07:15PM  
May-31-19 08:44AM  
May-30-19 08:00AM  
May-29-19 08:00AM  
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery. Its lead product candidate is DEXTENZA (dexamethasone ophthalmic insert), which has completed two Phase III clinical trials for the treatment of post-surgical ocular pain and inflammation, and allergic conjunctivitis; and DEXTENZA, which is in Phase III clinical trials for the treatment of dry eye diseases. The company also develops OTX-TP (intracanalicular travoprost insert), which is in Phase III clinical trials for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension; OTX-TIC, an intracameral travoprost implant, which is in Phase I clinical trials for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; OTX-TKI, an intravitreal tyrosine kinase inhibitor implant, which is in Phase I clinical trials for the treatment of wet age-related macular degeneration(AMD). Its various preclinical programs include OTX- BPI for the treatment of acute ocular pain; OTX-BDI to treat post-operative Pain, and inflammation and bacterial infection; OTX-CSI to treat dry-eye disease; and OTX-IVT, an intravitreal aflibercept implant for the treatment of wet AMD and other back-of-the-eye diseases. The company has strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SUMMER ROAD LLC10% OwnerOct 16Buy10.484374,5805,618,861Oct 20 04:06 PM
SUMMER ROAD LLC10% OwnerMay 19Buy5.50363,6361,999,9985,618,424May 21 04:15 PM
SUMMER ROAD LLC10% OwnerMar 24Buy4.8735,052170,7145,254,788Mar 24 09:42 PM
SUMMER ROAD LLC10% OwnerMar 23Buy4.6664,948302,3655,219,736Mar 24 09:42 PM
SUMMER ROAD LLC10% OwnerMar 20Buy4.529,10041,1195,154,788Mar 24 09:42 PM
SUMMER ROAD LLC10% OwnerMar 19Buy4.6340,900189,2245,145,688Mar 20 09:34 PM
SUMMER ROAD LLC10% OwnerMar 18Buy4.62344,9381,594,2005,104,788Mar 20 09:34 PM
SUMMER ROAD LLC10% OwnerMar 17Buy4.66550,0002,562,8904,759,850Mar 17 09:35 PM
SUMMER ROAD LLC10% OwnerMar 16Buy4.16194,262807,2174,209,850Mar 17 09:35 PM
SUMMER ROAD LLC10% OwnerMar 13Buy4.63210,800975,9834,015,588Mar 17 09:35 PM
Opaleye Management Inc.10% OwnerJan 02Buy3.9015,00058,5084,918,500Jan 03 07:45 PM
Opaleye Management Inc.10% OwnerDec 30Buy3.9720,00079,4104,903,500Jan 02 05:15 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.